Cristina Mastini
Overview
Explore the profile of Cristina Mastini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Villa M, Sharma G, Malighetti F, Mauri M, Arosio G, Cordani N, et al.
Br J Cancer
. 2024 Oct;
131(11):1781-1795.
PMID: 39478125
Background: Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive T-cell lymphoma, classified into ALK-positive and ALK-negative subtypes, based on the presence of chromosomal translocations involving the ALK gene....
2.
Crespiatico I, Zaghi M, Mastini C, DAliberti D, Mauri M, Mercado C, et al.
Blood
. 2024 Jan;
143(14):1399-1413.
PMID: 38194688
SETBP1 mutations are found in various clonal myeloid disorders. However, it is unclear whether they can initiate leukemia, because SETBP1 mutations typically appear as later events during oncogenesis. To answer...
3.
Mota I, Patrucco E, Mastini C, Mahadevan N, Thai T, Bergaggio E, et al.
Nat Cancer
. 2023 Jul;
4(7):1016-1035.
PMID: 37430060
Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is treated with ALK tyrosine kinase inhibitors (TKIs), but the lack of activity of immune checkpoint inhibitors (ICIs) is poorly understood....
4.
Mastini C, Campisi M, Patrucco E, Mura G, Ferreira A, Costa C, et al.
Sci Transl Med
. 2023 Jun;
15(702):eabo3826.
PMID: 37379367
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) show potent efficacy in several ALK-driven tumors, but the development of resistance limits their long-term clinical impact. Although resistance mechanisms have been...
5.
Trape G, De Angelis G, Morucci M, Tarnani M, De Gregoris C, Di Veroli A, et al.
Eur J Haematol
. 2023 May;
111(2):311-317.
PMID: 37231885
Objectives: Aim of the study was to evaluate the role of a Domiciliary Hematologic Care Unit (DHCU) compared to standard DH setting in the active frontline treatment with hypomethylating agents...
6.
Steidl C, Aroldi A, Mologni L, Crespiatico I, Fontana D, Mastini C, et al.
Leuk Res
. 2022 Jun;
118:106861.
PMID: 35653850
Acute myeloid leukemia (AML) identifies a heterogeneous group of clonal disorders, both clinically and genetically. A large number of mutations have been described in AML, although only a few are...
7.
Arosio G, Sharma G, Villa M, Mauri M, Crespiatico I, Fontana D, et al.
Cancers (Basel)
. 2021 Sep;
13(17).
PMID: 34503232
Anaplastic lymphoma kinase-positive (ALK+) anaplastic large-cell lymphoma (ALCL) is a subtype of non-Hodgkin lymphoma characterized by expression of the oncogenic NPM/ALK fusion protein. When resistant or relapsed to front-line chemotherapy,...
8.
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia
Fontana D, Ramazzotti D, Aroldi A, Redaelli S, Magistroni V, Pirola A, et al.
Hemasphere
. 2020 Nov;
4(6):e497.
PMID: 33196013
Atypical chronic myeloid leukemia (aCML) is a -negative clonal disorder, which belongs to the myelodysplastic/myeloproliferative group. This disease is characterized by recurrent somatic mutations in , and genes, as well...
9.
Menotti M, Ambrogio C, Cheong T, Pighi C, Mota I, Cassel S, et al.
Nat Med
. 2018 Dec;
25(1):130-140.
PMID: 30510251
In T lymphocytes, the Wiskott-Aldrich Syndrome protein (WASP) and WASP-interacting-protein (WIP) regulate T cell antigen receptor (TCR) signaling, but their role in lymphoma is largely unknown. Here we show that...
10.
Redaelli S, Ceccon M, Zappa M, Sharma G, Mastini C, Mauri M, et al.
Cancer Res
. 2018 Oct;
78(24):6866-6880.
PMID: 30322862
: Targeted therapy changed the standard of care in ALK-dependent tumors. However, resistance remains a major challenge. Lorlatinib is a third-generation ALK inhibitor that inhibits most ALK mutants resistant to...